Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions

被引：0
|
作者：
Claire E. P. Smith
Paul K. Marcom
Zahi Mitri
Naomi Y. Ko
机构：
[1] Boston University School of Medicine,Duke Cancer Center
[2] Boston Medical Center,undefined
[3] Duke University Hospital,undefined
[4] Oregon Health and Science University,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 196卷
关键词：
Breast Cancer; HER2; Trastuzumab; Neoplasm metastasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：215 / 220
页数：5
相关论文
共 50 条
  • [1] Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions
    Smith, Claire E. P.
    Marcom, Paul K.
    Mitri, Zahi
    Ko, Naomi Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (01) : 215 - 220
  • [2] Predictors of long-term durable response in de novo HER2 positive metastatic breast cancer and the real world treatment experience at two institutions
    Smith, Claire E.
    Marcom, Paul K.
    Zahi, Mitri
    Ko, Naomi
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
    Pooja Murthy
    Kelley M. Kidwell
    Anne F. Schott
    Sofia D. Merajver
    Jennifer J. Griggs
    Jeffrey D. Smerage
    Catherine H. Van Poznak
    Max S. Wicha
    Daniel F. Hayes
    N. Lynn Henry
    Breast Cancer Research and Treatment, 2016, 155 : 589 - 595
  • [4] Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
    Murthy, Pooja
    Kidwell, Kelley M.
    Schott, Anne F.
    Merajver, Sofia D.
    Griggs, Jennifer J.
    Smerage, Jeffrey D.
    Van Poznak, Catherine H.
    Wicha, Max S.
    Hayes, Daniel F.
    Henry, N. Lynn
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 589 - 595
  • [5] Real-word incidence and management of durable complete response in de novo metastatic HER2-positive breast cancer.
    Smith, Claire Elizabeth Powers
    Marcom, Paul Kelly
    Mitri, Zahi Ibrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study
    Liang, Xu
    Gui, Xinyu
    Yan, Ying
    Di, Lijun
    Liu, Xiaoran
    Li, Huiping
    Song, Guohong
    ONCOLOGIST, 2024, 29 (02): : e198 - e205
  • [7] Clinical predictors of long-term survival in Her2-positive (HER2+) metastatic breast cancer (MBC)
    Murthy, Pooja
    Kidwell, Kelley M.
    Thomas, Dafydd G.
    Griggs, Jennifer J.
    Merajver, Sofia D.
    Schott, Anne F.
    Smerage, Jeffrey B.
    Van Poznak, Catherine H.
    Wicha, Max
    Hayes, Daniel F.
    Henry, N. Lynn
    CANCER RESEARCH, 2015, 75
  • [8] Real-world survival of Danish patients with HER2-positive metastatic breast cancer
    Artzi, Daniel
    Berg, Tobias
    Celik, Alan
    Kumler, Iben
    Kenholm, Julia
    Al-Rawi, Sami
    Jensen, Maj-Britt
    Andersson, Michael
    Knoop, Ann
    ACTA ONCOLOGICA, 2023, 62 (06) : 601 - 607
  • [9] Real-world efficaccy of dual antiHER2 therapy in first line metastatic HER2-positive breast cancer and the possibility of prediction of long-term response
    Krizic, Marija
    Silovski, Tajana
    Popovic, Marina
    Plavetic, Natalija Dedic
    CANCER RESEARCH, 2023, 83 (05)
  • [10] A real-world evidence study of treatment patterns among patients with HER2-positive metastatic breast cancer
    Collins, Jenna
    Nordstrom, Beth
    Kwong, Jackie
    Murphy, Brian
    Pavilack, Melissa
    CANCER RESEARCH, 2021, 81 (04)
12345